Compare BGSF & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | ACET |
|---|---|---|
| Founded | 2007 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 69.6M |
| IPO Year | 2013 | 2017 |
| Metric | BGSF | ACET |
|---|---|---|
| Price | $6.07 | $6.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $9.00 | ★ $56.00 |
| AVG Volume (30 Days) | 24.1K | ★ 97.5K |
| Earning Date | 03-11-2026 | 03-12-2026 |
| Dividend Yield | ★ 32.36% | N/A |
| EPS Growth | ★ 67.37 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $272,499,000.00 | N/A |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.91 | $0.45 |
| 52 Week High | $8.20 | $9.05 |
| Indicator | BGSF | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 44.63 |
| Support Level | $5.93 | $6.54 |
| Resistance Level | $6.38 | $8.34 |
| Average True Range (ATR) | 0.26 | 0.43 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 39.77 | 12.76 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.